<DOC>
	<DOCNO>NCT02927938</DOCNO>
	<brief_summary>Most patient acute myeloid leukemia ( AML ) achieve complete remission ( CR ) follow induction chemotherapy . However , large majority subsequently relapse succumb disease . Currently , cytogenetics molecular aberration best prognostic indicator ; however , factor prognosticate accurately individual patient . Overall , majority patient favorable intermediate-risk AML experience relapse . Prognosis relapse dismal five-year overall survival rate le 10 % . A leukemia stem cell ( LSC ) paradigm may explain failure CR reliably translate cure . This study undertaken determine whether presence LSCs prognostic value well determine whether presence LSCs predictive value . This study observational component , whereby intent evaluate whether presence absence LSCs prognostic . This study also interventional component use LSC status determine whether favorable intermediate risk AML patient CR receive consolidation chemotherapy allogeneic HCT .</brief_summary>
	<brief_title>Leukemia Stem Cell Detection Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>1 . Must previously sign specimen procurement protocol consent associate leukemia stem cell assay ( `` Step 1 inform consent '' ) prior start AML therapy . 2 . Age 18 year old 3 . New diagnosis AML , APL , confirm bone marrow aspirate/biopsy review institutional hematopathologist 4 . Completion induction therapy , define Investigator postinduction bone marrow biopsy . 1 . Any debilitate medical psychiatric illness would preclude ability follow study procedure . 2 . Indeterminate leukemia stem cell assay result diagnosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>